Physician profile
Steven T Chetham
NPI 1316962376
$6,725.04
in general payments reported to CMS, 2019-2025
24 companies · $23.01 in 2025
The $23.01 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $1,471 · 2021: $1,692 · 2022: $1,041 · 2023: $1,029 · 2024: $48.21 · 2025: $23.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,510.25 | 2019-2023 | Linzess, Viberzi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,075.17 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $787.84 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $484.39 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Qol Medical, LLC | $365.81 | 2019-2023 | Sucraid |
| Gilead Sciences, INC. | $341.87 | 2019-2023 | |
| Pfizer INC. | $248.10 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $142.16 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $112.17 | 2022-2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $110.97 | 2019-2023 | Ocaliva |
| Genzyme Corporation | $98.85 | 2022-2023 | |
| Celgene Corporation | $86.62 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $72.87 | 2019-2023 | Dificid |
| Alfasigma USA, INC. | $42.31 | 2020 | |
| Ucb, INC. | $38.29 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34.57 | 2023 | Renflexis, Hadlima |
| Ferring Pharmaceuticals INC. | $29.95 | 2021-2023 | Rebyota |
| Shionogi INC | $29.50 | 2019 | |
| Lilly USA, LLC | $27.26 | 2024 | Omvoh |
| Allergan, INC. | $20.81 | 2020 | |
| Fresenius Kabi USA, LLC | $18.24 | 2023 | Idacio |
| Redhill Biopharma INC. | $17.29 | 2021 | |
| Amgen INC. | $16.50 | 2023 | Amjevita |
| Braintree Laboratories, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Chetham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.